Protocol for developing a melanoma brain metastasis mouse model for preclinical drug testing and brain tumor progression monitoring.

Jared Almazan, Tursun Turapov, Sheri L Holmen

Abstract read

In one paragraph

Article in STAR protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jared AlmazanHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA. Electronic address: jared.almazan@hci.utah.edu.

Tursun TurapovHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA.

Sheri L HolmenHuntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Oncological Sciences, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA; Department of Surgery, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA. Electronic address: sheri.holmen@hci.utah.edu.

Funding

CTSA Predoctoral T32 at University of Utah: Spheres of Translation Across the Research Spectrum (STARS) Training ProgramT32TR004392 · NCATS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI ANGELA FAGERLIN, Keke Celeste Fairfax · 2023 to 2026

$1.3M

NCATS NIH HHS T32 TR004392

6 · The paper itself

Abstract

We present a protocol to generate a murine model of established melanoma brain metastases by intracranially injecting tumor cells into newborn "glowing head" C57BL/6 syngeneic mice, which are tolerized to both GFP and luciferase. First, we describe steps for cell and animal preparation. We then detail the utilization of bioluminescent imaging to monitor brain tumor progression. This model enables the evaluation of therapeutic efficacy against established melanoma brain metastases. For complete details on the use and execution of this protocol, please refer to Almazan et al.

Indexed as

Brain NeoplasmsDisease Models, AnimalMelanomaAnimalsCell Line, TumorDisease ProgressionDrug Evaluation, PreclinicalLuminescent MeasurementsMiceMice, Inbred C57BLCancerHealth SciencesModel OrganismsMolecular Biology

Identifiers

PMID40944916

DOI10.1016/j.xpro.2025.104081

PMCPMC12491511

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.